SCHEMBL2360001

SCHEMBL2360001

O=C1/C(=C\c2ccccc2)CCc2c1[nH]c1ccc(Cl)c(Cl)c21

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 7/20 0.63
MAPT P10636 6/20 0.63
SMN1; SMN2 Q16637 3/20 0.63
ALDH1A1 P00352 3/20 0.63
NPC1 O15118 2/20 0.63
POLB P06746 2/20 0.63
LMNA P02545 1/20 0.63
HTT P42858 2/20 0.49
MEN1 O00255 1/20 0.49
MAPK1 P28482 1/20 0.49
KMT2A Q03164 1/20 0.49
CYP1A2 P05177 3/20 0.48
MAOB P27338 6/20 0.42
F3 P13726 1/20 0.42
KDM4E B2RXH2 2/20 0.41
L3MBTL1 Q9Y468 1/20 0.40
MIF P14174 2/20 0.39
MGAM O43451 1/20 0.37
GAA P10253 1/20 0.37
SI P14410 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2360003 1.00 RAB9A (0.63) RAB9AMAPTSMN1; SMN2ALDH1A1NPC1
SCHEMBL2358563 0.79 RAB9A (0.72) RAB9AMAPTSMN1; SMN2ALDH1A1NPC1
SCHEMBL12441076 0.79 RAB9A (0.72) RAB9AMAPTSMN1; SMN2ALDH1A1NPC1
SCHEMBL2358567 0.79 RAB9A (0.72) RAB9AMAPTSMN1; SMN2ALDH1A1NPC1
SCHEMBL14688216 0.74 KDM4E (0.46) MAPTSMN1; SMN2ALDH1A1POLBLMNA
SCHEMBL26154431 0.73 RAB9A (1.00) RAB9AMAPTSMN1; SMN2ALDH1A1NPC1
SCHEMBL22529407 0.69 KDM4E (0.52) MAPTSMN1; SMN2ALDH1A1POLBLMNA
SCHEMBL2359337 0.69 KDM4E (0.56) MAPTSMN1; SMN2ALDH1A1POLBLMNA
SCHEMBL2360319 0.68 DDB1 (0.43) MAOBPARP1
SCHEMBL23633272 0.68 CYP1A2 (1.00) RAB9AMAPTSMN1; SMN2ALDH1A1NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20170121285-A1 Selective androgen receptor modulators RADIUS HEALTH INC (US) 2017-05-04 US disclosed
US-20170121285-A1 Selective androgen receptor modulators RADIUS HEALTH INC (US) 2017-05-04 US disclosed
US-20170121285-A1 Selective androgen receptor modulators RADIUS HEALTH INC (US) 2017-05-04 US disclosed
EP-2531029-B1 SELECTIVE ANDROGEN RECEPTOR MODULATORS RADIUS HEALTH INC (US) 2016-10-19 EP disclosed
EP-2531029-B1 SELECTIVE ANDROGEN RECEPTOR MODULATORS RADIUS HEALTH INC (US) 2016-10-19 EP disclosed
US-20150266821-A1 SELECTIVE ANDROGEN RECEPTOR MODULATORS RADIUS HEALTH INC (US) 2015-09-24 US disclosed
US-20150266821-A1 SELECTIVE ANDROGEN RECEPTOR MODULATORS RADIUS HEALTH INC (US) 2015-09-24 US disclosed
US-20150266821-A1 SELECTIVE ANDROGEN RECEPTOR MODULATORS RADIUS HEALTH INC (US) 2015-09-24 US disclosed
US-8987319-B2 Selective androgen receptor modulators RADIUS HEALTH, INC. (US) 2015-03-24 US disclosed
US-8987319-B2 Selective androgen receptor modulators RADIUS HEALTH, INC. (US) 2015-03-24 US disclosed
US-8987319-B2 Selective androgen receptor modulators RADIUS HEALTH, INC. (US) 2015-03-24 US disclosed
US-20130041007-A1 Selective Androgen Receptor Modulators RADIUS HEALTH, INC. 2013-02-14 US disclosed
US-20130041007-A1 Selective Androgen Receptor Modulators RADIUS HEALTH, INC. 2013-02-14 US disclosed
US-20130041007-A1 Selective Androgen Receptor Modulators RADIUS HEALTH, INC. 2013-02-14 US disclosed
EP-2531029-A1 SELECTIVE ANDROGEN RECEPTOR MODULATORS Radius Health, Inc. (US) 2012-12-12 EP disclosed
WO-2011097496-A1 SELECTIVE ANDROGEN RECEPTOR MODULATORS RADIUS HEALTH, INC. (US) 2011-08-11 WO disclosed
WO-2011097496-A1 SELECTIVE ANDROGEN RECEPTOR MODULATORS RADIUS HEALTH, INC. (US) 2011-08-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170121285-A1 Selective androgen receptor modulators AR, SHBG, FSHR RAB9A 3154/4885MAPT 2267/4885SMN1; SMN2 736/4885
US-20150266821-A1 SELECTIVE ANDROGEN RECEPTOR MODULATORS AR, SHBG, FSHR RAB9A 3153/4885MAPT 2263/4885SMN1; SMN2 728/4885
US-20130041007-A1 Selective Androgen Receptor Modulators AR, SHBG, GPR119 RAB9A 3532/4885MAPT 2494/4885SMN1; SMN2 1034/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.